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Evaluation of the immunological 
profile of antibody-functionalized 
metal-filled single-walled carbon 
nanocapsules for targeted 
radiotherapy
Aritz Perez Ruiz de Garibay1, Cinzia Spinato1, Rebecca Klippstein2, Maxime Bourgognon2, 
Markus Martincic3, Elzbieta Pach4, Belén Ballesteros4, Cécilia Ménard-Moyon1,  
Khuloud T. Al-Jamal2, Gerard Tobias3 & Alberto Bianco1
This study investigates the immune responses induced by metal-filled single-walled carbon nanotubes 
(SWCNT) under in vitro, ex vivo and in vivo settings. Either empty amino-functionalized CNTs 
[SWCNT-NH2 (1)] or samarium chloride-filled amino-functionalized CNTs with [SmCl3@SWCNT-mAb 
(3)] or without [SmCl3@SWCNT-NH2 (2)] Cetuximab functionalization were tested. Conjugates were 
added to RAW 264.7 or PBMC cells in a range of 1 μg/ml to 100 μg/ml for 24 h. Cell viability and IL-6/
TNFα production were determined by flow cytometry and ELISA. Additionally, the effect of SWCNTs 
on the number of T lymphocytes, B lymphocytes and monocytes within the PBMC subpopulations 
was evaluated by immunostaining and flow cytometry. The effect on monocyte number in living mice 
was assessed after tail vein injection (150 μg of each conjugate per mouse) at 1, 7 and 13 days post-
injection. Overall, our study showed that all the conjugates had no significant effect on cell viability 
of RAW 264.7 but conjugates 1 and 3 led to a slight increase in IL-6/TNFα. All the conjugates resulted 
in significant reduction in monocyte/macrophage cell numbers within PBMCs in a dose-dependent 
manner. Interestingly, monocyte depletion was not observed in vivo, suggesting their suitability for 
future testing in the field of targeted radiotherapy in mice.
In the past years, taking advantage of their unique physicochemical properties, both multi-walled carbon nano-
tubes (MWCNTs) and single-walled carbon nanotubes (SWCNTs) have emerged as promising tools for biomed-
ical applications1–4. For instance, their favorable electrical properties and their responsiveness to changes in the 
surrounding environment allow carbon nanotubes (CNTs) to act as promising biosensors5. In addition, thanks 
to their small diameter, high aspect ratio and toughness, CNTs have been proposed as atomic force microscopy 
(AFM) tip nanoinjectors to facilitate the insertion of molecules into cells in a target point6,7. Moreover, due to their 
capability to penetrate into cell membranes8,9, CNTs can work as efficient gene delivery systems10–15. They have 
been reported to promote gene silencing by forming supramolecular complexes between cationic functionalized 
CNTs and short RNA oligomers, which could help in the treatment of cancer or immune diseases10–15. In a sim-
ilar way, with the appropriate functionalization, CNTs can deliver drugs to specific target cells (i.e. cancer cells) 
in order to enhance the effect of the drug they are carrying as it was demonstrated for several CNT-doxorubicin 
complexes16–18. Comparing the number of studies conducted in those fields, little work has been carried out 
regarding the use of CNTs as vectors for radionuclides to be exploited either for cancer diagnosis or therapy19–25. 
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Moreover, all these studies have focused on the attachment of chosen moieties to the external walls, but we can 
take also advantage of the presence of the inner cavity to host biomedically relevant payloads26. In fact, it is pos-
sible to fill the nanotubes with a therapeutic or imaging cargo whilst the external wall remains available for their 
derivatization with dispersing and targeting molecules. Encapsulation of molecules inside the nanotubes also has 
the advantage of protecting and isolating them from the external environment and avoid their free circulation 
in the body. Among the many examples of filled CNTs for bioapplications, most researches have focused on the 
encapsulation of drug molecules for therapeutic purposes, while only few have described biomedical imaging 
with magnetic nanoparticles (for magnetic resonance imaging)27 and radionuclides (via single-photon emission 
computed tomography)28.
We have recently reported a complete study describing the design of antibody-functionalized SWCNTs filled 
with radioactivable metals towards targeted anticancer therapy29. To this purpose, steam-purified SWCNTs were 
filled with samarium or lutetium chloride. After high-temperature sealing, SWCNTs were covalently functional-
ized with the monoclonal antibody (mAb) Cetuximab (Erbitux®) targeting the epidermal growth factor recep-
tor (EGFR), overexpressed on several cancer cells. Our study highlighted the great possibilities offered by these 
filled and functionalized CNTs, which were able to internalize more efficiently into EGFR positive cancer cells. 
Moreover, these findings prompted us to lead a thorough investigation of the immunological impact of these 
conjugates.
A suitable nanomaterial should prevent several outcomes in order to be biocompatible, such as triggering 
immune reactions, acute inflammatory responses or cytotoxicity within the cells to which it is targeted, or cells 
of first-line exposure30. Classically, two lines of defense are known. Innate immunity is the first activated line 
responsible for combating foreign organisms or substances, mainly via complement activation and macrophage 
and neutrophil actions. This leads to the elimination of the intruders and further activation of the adaptive immu-
nity. Adaptive responses, on the other hand, are durable specific reactions triggered by T and B lymphocytes. It 
is crucial to study the impact of nanomaterials, including CNTs, on these immune cells and the outcomes of this 
encounter31. A recent review has reported a helpful overview on the immune impact of carbon nanomaterials 
to guide future research on their immunological applications in biomedicine32. The studies of the effects on the 
immune systems are not limited only to carbon materials. Other types of nanoparticles and nanomaterials may 
result immune compatible or could exert an immune specific action depending on their surface functionalization 
and chemical composition33–35.
This work aimed to analyze the immunological profiles of a wide range of doses of three different 
SWCNT conjugates: empty amino-functionalized CNTs [SWCNT-NH2 (1)] and samarium chloride-filled 
amino-functionalized CNTs without [SmCl3@SWCNT-NH2 (2)] or with [SmCl3@SWCNT-mAb (3)] Cetuximab 
functionalization in murine (RAW 264.7 macrophages) and human cells (peripheral blood mononuclear cells, 
PBMCs). Parameters tested in vitro include viability, cell activation and cytokine production. Additionally, the 
effects of the conjugates on PBMC viability and number of cell subpopulations [T lymphocytes (LT), B lympho-
cytes (LB) and monocytes/macrophages] were evaluated. Finally, the percentage of monocyte/macrophage popu-
lation within PBMCs after tail vein injection of the conjugates in C57Bl/6 mice was determined.
Results
Functionalization of SWCNTs. In this study we have compared the immunological impact of three dif-
ferent types of functionalized SWCNTs: SWCNT-NH2 (1), SmCl3@SWCNT-NH2 (2) and SmCl3@SWCNT-mAb 
(3). To evaluate the eventual effect of the presence of filling material (SmCl3) on cells, we have employed both 
empty and samarium-filled CNTs. Purified and shortened SWCNTs were initially functionalized by nitrene 
cycloaddition with amino-terminating triethylene glycol (TEG) chains, with the aim of increasing their water 
dispersibility and biocompatibility29. The free amine loading of SWCNT-NH2 (1) and SmCl3@SWCNT-NH2 (2) 
calculated by the Kaiser test was 104 μ mol/g and 90 μ mol/g, respectively. Functionalized SmCl3-filled CNTs 2 
were then further derivatized with the targeting antibody Cetuximab by coupling reaction on the TEG terminal 
amino group, obtaining SmCl3@SWCNT-mAb (3). The structural representation of the three conjugates is shown 
in Fig. 1. The morphological characterization of all conjugates was carried out using different spectroscopic and 
microscopic techniques. TEM images of the precursors of empty SWCNT-NH2 (1) confirmed that the nanotubes 
remained structurally intact throughout all functionalization steps (Fig. 2). The comparison of the thermogravi-
metric analysis between the precursor pristine nanotubes and the protected SWCNT-NH2 (1) allowed to assess 
the degree of functionalization (Figure S1). The filled SmCl3@SWCNT-NH2 (2) and SmCl3@SWCNT-mAb (3) 
correspond to the same batches of tubes reported in our previous work29. Additional characterizations using high 
resolution transmission microscopy (HRTEM), high-angle annular dark-field scanning transmission electron 
microscopy (HAADF-STEM) and energy-dispersive X-ray spectroscopy (EDX) are shown in Fig. 2. HRTEM 
images of SmCl3@SWCNT precursors (Fig. 2d) confirmed that the encapsulated metal halide is crystalline and 
its structure is in good agreement with the hexagonal P63/m structure of the bulk material. After functionaliza-
tion with amine groups the SWCNTs remained filled as shown in the HAADF-STEM image of sample SmCl3@
SWCNT-NH2 (2) (Fig. 2e). Intensity in HAADF-STEM images is proportional to the atomic number, therefore 
the metal halide, heavier than the carbon from the SWCNTs, appears as bright lines. The presence of the amine 
groups in this sample is proven by EDX spectroscopy, where the signal corresponding to nitrogen is observed as 
a shoulder at 0.4 keV (Fig. 2h). To assess the functionalization with the antibody Cetuximab, SmCl3@SWCNT-
mAb (3) was immunostained with a secondary antibody conjugated with gold nanoparticles (AuNPs)29. Both the 
AuNPs and the samarium chloride filling are visible with bright intensity in the HAADF-STEM image in Fig. 2f. 
EDX composition profiles demonstrate that the large bright dots correspond to the AuNPs, and their location 
on the SWCNTs is an indication of the successful attachment of the antibody Cetuximab onto the SmCl3 filled 
SWCNTs. Overall, these analyses confirm that the structural integrity was not affected during the organic and 
biological functionalization of the filled SWCNTs29. The three conjugates differ either in the absence or presence 
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of the samarium chloride filling (conjugates 1 and 2, respectively), the presence of open or closed ends (conju-
gates 1 and 2, respectively)36 or the absence or presence of targeting antibody (conjugates 2 and 3, respectively).
Viability, cell activation and cytokine production in RAW 264.7 macrophages in vitro. We pre-
viously reported that SmCl3@SWCNT-NH2 (2) and SmCl3@SWCNT-mAb (3) did not display cytotoxic effects in 
U87 and CHO cells29. However, a broader analysis on immune cells is needed to demonstrate the safe use of these 
conjugates for future applications in the biomedical field. For this purpose, the first step was to explore the impact 
of the SWCNT conjugates in vitro on the murine RAW 264.7 macrophage cell line. After 24 hour incubation with 
1, 10, 25, 50 and 100 μ g/ml of either of the conjugates, no significant reduction in overall cell viability (Fig. 3) or 
apoptotic cell numbers (Supplementary Figure S2) was observed.
Since one of the main roles of immune cells is to respond to foreign bodies, cell activation was investigated by 
analyzing expression of CD86 marker, a co-stimulatory molecule expressed in activated macrophages. SWCNT 
exposure to cells did not cause cellular activation with any of the conjugates at all concentrations tested (p > 0.05) 
(Fig. 4).
Macrophage activation leads to production of pro-inflammatory cytokines. Titers of IL-6 and TNFα present 
in the supernatants of the treated cells, determined by ELISA, showed negligible values for both cytokines for cells 
treated with SmCl3@SWCNT-NH2 (2), similar to untreated cells (Fig. 5). Only a small but significant increase 
in both cytokines was detected in cells treated with SWCNT-NH2 (1) or SmCl3@SWCNT-mAb (3). These values 
however were at least 3-fold lower than values obtained in the positive control. Altogether, these results suggested 
low toxicity threshold for SWCNTs (1–3) in RAW 264.7 macrophages.
Effect of SWCNTs on human PBMC subpopulations ex vivo. As previously suggested, the cytotoxic 
effects of SWCNTs depend on the cell type37. Therefore, we continued our study using human primary PBMCs, 
which were obtained by Ficoll-Histopaque density gradient centrifugation of leukocyte-rich buffy coats from 
healthy adult donors. PBMCs were cultured for 6 hours before being treated with 1, 10, 25, 50 and 100 μ g/ml 
of either of the conjugates for 24 hours. Then, viability was evaluated by flow cytometry using Annexin V and 
propidium iodide. In addition, cytokine levels were also analyzed from culture supernatants. Taking into account 
that the 3 types of cells (i.e. LT, LB and monocytes/macrophages) constituting the PBMCs are unlikely to react 
equally to SWCNTs, each of the subpopulations, tagged with cell specific fluorescent markers were analyzed 
separately by flow cytometry. None of the conjugates affected the overall cell viability or LT and LB population 
cell numbers (number of events) (Fig. 6). Exceptionally, the CD14+ population (monocytes/macrophages) was 
adversely affected. Cell counts were significantly reduced in a concentration-dependent manner starting at con-
centrations > 50 μ g/ml [SWCNT-NH2 (1) and SmCl3@SWCNT-NH2 (2)] and > 1 μ g/ml (SmCl3@SWCNT-mAb 
(3)]. The viability of cells treated with the latter was also affected at concentrations higher than 25 μ g/ml.
These results were further confirmed upon cytokine analysis where prominent increase in IL-6 and TNFα 
production was observed, more significantly with SWCNT-NH2 (1) and SmCl3@SWCNT-mAb (3), in a 
concentration-dependent manner with comparable values to that of the positive control reaching the same levels 
or sometimes surpassing the positive control (LPS + IFN-γ ) (Fig. 7).
Immunological impact of SWCNTs after in vivo administration. A pilot study in C57Bl/6 mice was 
undertaken to examine if the in vitro findings of this study are translated in vivo but using more therapeutically 
relevant doses. Five groups of 4 mice were injected with either 150 μ l of PBS (negative control), 3 mg/kg LPS 
(positive control) or 150 μ l of a 1 mg/ml SWCNT dispersions, all via the tail vein except for the positive control.
The number of events of LT (CD3+ ), LB (CD45R/B220+ ) and monocytes/macrophages (CD11b+ ) in the 
PBMCs were analyzed at specific time points post-treatment (1, 7 and 13 days). In case of acute immunological 
reaction in vivo, an increase in the PBMC numbers is expected21.
Figure 1. Molecular structures of SWCNT-NH2 (1), SmCl3@SWCNT-NH2 (2) and SmCl3@SWCNT-mAb 
(3). The left-side open end of compounds 2 and 3 is meant to visually indicate the extended length of the 
nanotubes.
www.nature.com/scientificreports/
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Similar to what was observed in human PBMCs, no changes in the LT and LB populations cell number at 
any of the time points tested were found (data not shown). Unlike the ex vivo studies using human PBMCs, the 
murine monocytes population was not affected (Fig. 8). The positive control group showed an increased number 
of monocytes at 24 hours in comparison to the PBS-treated mice. These values returned to baseline at 7 days 
onwards post-treatment. The negative immune response following SWCNT treatments agreed with the cytokine 
production profiles (Supplementary Figure S3). No changes in weight mice was observed (data not shown).
Discussion
In the present study we have explored the immune response of three differently functionalized SWCNT con-
jugates at increasing concentrations in three experimental setups: in vitro, ex vivo and in vivo. For this purpose 
we have selected a sample of empty amino-functionalized CNTs, SWCNT-NH2 (1), a sample of samarium 
chloride-filled amino-functionalized CNTs, SmCl3@SWCNT-NH2 (2), and a sample of filled CNTs further func-
tionalized with the targeting antibody Cetuximab, SmCl3@SWCNT-mAb (3). Conjugates 1 and 2 were chosen to 
investigate possible effects determined by the presence of the filling material, since they are both functionalized 
with amino-terminating functionalities. SmCl3@SWCNT-mAb (3), represents a third conjugate type, possessing 
a bioactive moiety, and was obtained by derivatization of compound 2. A concentration range between 1 and 
100 μ g/ml was selected based on our previous findings29. The highest dose was supposed to trigger a certain 
Figure 2. Electron microscopy characterization of empty and SmCl3 filled SWCNT conjugates. Low 
resolution TEM images of pristine SWCNTs (a), Pht-protected SWCNT-NH2 1 (b) and SWCNT-NH2 1 (c). 
(d,g) HRTEM image of SmCl3@SWCNT precursor and corresponding EDX spectrum. (e,h) HAADF-STEM 
image of SmCl3@SWCNT-NH2 (2) showing the bright lines arising from the filling material and EDX spectrum 
showing the nitrogen signal associated with the attached amino functional groups. (f,i) Sm and Au EDX line 
profiles acquired in STEM mode showing the location of the filling compound and the gold nanoparticles 
(AuNPs) in SmCl3@SWCNT-mAb (3) after being immunostained with a secondary antibody conjugated with 
AuNPs.
www.nature.com/scientificreports/
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degree of cytotoxicity and it was necessary to determine the range of concentration that can be subsequently 
selected in a biomedical context (i.e. few tens of μ g/ml of injectable nanotubes)1.
Initial studies focused on analyzing cell viability, cell activation and production of cytokines using a murine 
macrophage cell line, following their incubation with SWCNTs in vitro. The assessment of macrophage response 
to CNTs is a central component in the evaluation of newly synthesized derivatives as it is known that these cells 
can quickly engulf CNTs, depending on their size and charge, contributing to the generation of an immune 
response. Following these initial studies, an ex vivo approach relying on human PBMCs from healthy donors was 
used. Cell viability and ability of CNTs to stimulate one or more of the cell subpopulations (cell numbers) were 
investigated. This was confirmed by measuring IL-6 and TNFα production triggered by exposure to SWCNTs. 
Finally, an in vivo pilot study was performed in C57Bl/6 mice to assess the impact of the conjugates on the PBMCs 
isolated at different time points.
Our results did not show remarkable effects on the viability of RAW 264.7 cells (Fig. 3), their activation (Fig. 4) 
or the production of cytokines (Fig. 5) even at high doses (up to 100 μ g/ml) of CNTs. A variable effect on cytokine 
production was noticed, especially on the IL-6 production but none reached the titres of the positive control. 
While SmCl3@SWCNT-NH2 (2) had only a negligible effect on cytokine release, SWCNT-NH2 (1) and SmCl3@
SWCNT-mAb (3) induced a small, but significant IL-6 production. The behavior of RAW 264.7 cells reported in 
the literature in response to SWCNTs is controversial. While some authors reported a cytotoxic effect with doses 
below 20 μ g/ml38, other researchers did not find any evidence to support these outcomes28. Our study was in 
agreement with the in vitro observations by Shvedova et al. using this cell line. In their study, SWCNTs produced 
significantly lower levels of TNFα and IL-1β than the positive control and did not significantly trigger apoptosis39.
The minimal effects of SWCNT-NH2 (1) and SmCl3@SWCNT-mAb (3) appeared more pronounced when 
using human PBMCs, with monocyte/macrophage population showing the highest reduction in number (Fig. 6). 
Figure 3. Viability of RAW 264.7 macrophages. Cells were incubated with the three SWCNT conjugates for 
24 h at increasing concentrations (1, 10, 25, 50 and 100 μ g/ml). DMSO (20%) was used as a positive control 
of death. Cell viability was determined with Annexin V/Propidium iodide staining and quantified by flow 
cytometry and no significant differences were observed for all compounds after 24 h of incubation (n = 3). 
Values are expressed as mean ± SD. **p < 0.01 with respect to untreated cells.
Figure 4. Activation of RAW 264.7 macrophages. RAW 264.7 cells were incubated with the SWCNT 
conjugates for 24 h at increasing concentrations (1, 10, 25, 50 and 100 μ g/ml), then stained for CD86+ 
expression. LPS combined with IFN-γ was used as a positive control of activation. Mean fluorescence intensity 
of CD86+ cells was measured to express degree of cell activation, following treatments with the conjugates. 
No significant differences were observed for any of the treatments. Values are expressed as mean ± SD (n = 3). 
*p < 0.05 with respect to untreated cells.
www.nature.com/scientificreports/
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The high titers of IL-6 and TNFα measured under these conditions are in agreement with these results (Fig. 7). 
A major effect was expected in this population for several reasons: (i) monocytes/macrophages are adherent cells 
and this might favor their interaction with CNTs; (ii) these types of phagocytic cells tend to internalize higher 
amounts of CNTs in comparison to LT and LB40–42; and (iii) CNTs have been shown to specifically activate mono-
cytes, but not other immune cells (i.e. T lymphocytes), by analyzing their gene expression profiles43.
In the case of CNTs, different parameters can affect cell behavior, including the degree of dispersibility, the 
length of the CNTs, the amount of functional groups or the type of cells analyzed37. Besides, it is important to 
note that the toxic effects are normally dependent on the administered doses of CNTs44,45. As it has been previ-
ously reported, pristine, non-functionalized long CNTs are toxic39,46,47, while functionalization has been shown to 
decrease the toxic effect in several studies42,48–51. In fact, Dumortier et al. reported that functionalized SWCNTs 
do not alter the immune response of murine primary cells42. In another study, Delogu et al. demonstrated that 
different types of MWCNTs did not show cytotoxic effects on a wide variety of primary human immune cells52.
The fact that conjugates 1 and 3 exerted more pronounced immunological effect than conjugate 2 can be 
attributed to a couple of factors. SWCNT-NH2 (1) and SmCl3@SWCNT-NH2 (2) differ by two characteristics: 
the absence/presence of the filling and the open or closed ends, respectively. While the filling may not have, 
in this case, any harmful effect, the open-ended nature of SWCNT-NH2 (1) may have resulted in an increased 
cytotoxicity. This could be explained taking into account that the end caps of open SWCNTs may have sev-
eral dangling bonds, which are highly reactive sites53 that tend to interact and affect cell integrity. Differently, in 
SmCl3@SWCNT-NH2 (2), the majority of the tubes are closed and devoid of dangling bonds, as a result of the 
employed molten phase filling process which was performed at high temperature (900 °C). In fact, during the 
cooling step which follows the high-temperature filling, the tips of the CNTs close on themselves engendering 
sealed tubes36. The close-ended filled nanotubes are also referred to as “carbon nanocapsules”. This might have 
resulted in SmCl3@SWCNT-NH2 (2) being more biocompatible. Conjugates (1) and (2) were obtained by func-
tionalization of the corresponding steam-treated SWCNTs with a TEG precursor29. TEG chains on the sidewalls 
of the SWCNTs (Fig. 1) generally increase the water-dispersibility of the CNTs thanks to their hydrophilic nature. 
The preferred use of a short linker, TEG, over the long-chained polyethyleneglycol (PEG) in this instance was 
solely based on the ease of synthetic reaction using the former; unreacted PEG was found difficult to be removed 
from SWCNTs following chemical functionalization. Unexpectedly, these chains did not completely fulfill the 
requirements in terms of dispersibility. However, we considered the dispersibility of the conjugates to be suffi-
ciently high to perform the different in vitro and in vivo experiments (Supplementary Figure S4).
Figure 5. Cytokine production by RAW 264.7 macrophages. RAW 264.7 macrophages were incubated 
with the SWCNT conjugates for 24 h at increasing concentrations (1, 10, 25, 50 and 100 μ g/ml), followed 
by measurements of IL-6 (top) and TNFα (bottom) cytokine production by ELISA. Values are expressed as 
mean ± SD (n = 3). The absence of bars indicates negligible levels. **p < 0.01 with respect to untreated cells.
www.nature.com/scientificreports/
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Figure 6. Effect of treatments with conjugates on PBMC viability and subpopulation cell numbers. PBMCs 
were incubated with the SWCNT conjugates for 24 h at increasing concentrations (1, 10, 25, 50 and 100 μg/ml),  
followed by flow cytometry measurements via propidium iodide staining to determine cell viability. Further 
staining was performed for CD3 (T lymphocytes, LT), CD19 (B lymphocytes, LB) or CD14 (monocytes/
macrophages) to determine cell numbers within each of the subpopulation by flow cytometry. DMSO was used 
as a positive control. Percentage cell viability (bars) (PI staining) and number of positive events (black lines) 
are shown for LT CD3+ , LB CD19+ and monocytes/macrophages CD14+ (from top to bottom). Values are 
expressed as mean ± SD (n = 3). **p < 0.01 with respect to untreated cells (% live cells). #p < 0.05 with respect to 
untreated cells (events vs. untreated).
Figure 7. Cytokine production by PBMCs. PBMCs were incubated with the SWCNT conjugates for 24 h at 
increasing concentrations (1, 10, 25, 50 and 100 μ g/ml), followed by measurements of IL-6 (top) and TNFα 
(bottom) cytokine production by ELISA. Values are expressed as mean ± SD (n = 3). The absence of bars 
indicates negligible levels. **p < 0.01 with respect to untreated cells.
www.nature.com/scientificreports/
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SmCl3@SWCNT-NH2 (2) was further derivatized with the targeting antibody Cetuximab by a coupling reac-
tion on the terminal amino group, yielding SmCl3@SWCNT-mAb (3). This functionalization step, intended to 
specifically target SmCl3@SWCNT-mAb (3) to EGFR-expressing cells as previously reported29, resulted in an 
improved dispersibility in physiological media. We hypothesize that the improved aqueous dispersibility of this 
conjugate compared to SWCNT-NH2 (1) and SmCl3@SWCNT-NH2 (2) resulted in a more efficient cell inter-
nalization of the former. This could have indirectly resulted in a significantly higher cytotoxic effect of (3) than 
(1) and (2), in the murine monocyte/macrophage population. Similar conclusions were previously obtained by 
other authors, where oxidized CNTs resulted in a more toxic effect than pristine CNTs on human T cells due to 
differences in aqueous dispersibility31,54.
The in vitro results suggested that a possible toxic effect may be encountered after systemic exposure to 
SWCNTs. Contrary to in vitro and ex vivo studies, as shown in Fig. 8 and Supplementary Figure S3, none of our 
compounds resulted in an activation of the immune system in vivo, with only the positive control showing altered 
values of monocytes/macrophages and cytokine production at the first time point (24 h) after the treatment. 
The lack of in vivo activation could be due to the dilution of the injected CNTs by total blood, yielding lower 
final blood concentrations than those achieved in in vitro studies. It has been previously demonstrated that the 
activation of the innate immunity (e.g. monocytes/macrophages) represents the first event in the response of the 
immune system to non-biocompatible CNTs31. This would be followed by cytokine secretion by monocytes/mac-
rophages, which may activate the helper LT and induce the differentiation of LB into antibody-secreting cells55,56. 
Taking this into account and comparing it to our results, we could confirm that at the dose proposed and through 
the intravenous route, our three compounds remained biocompatible through the duration of the treatment. 
These results are in accordance to those previously obtained with different types of MWCNTs and SWCNTs42,52.
In summary, our study showed that all the conjugates had no significant effect on cell viability or activation of 
RAW 264.7 cells but conjugates 1 and 3 led to a slight but significant increase in IL-6/TNFα , in a dose-dependent 
manner (in vitro studies). All the conjugates resulted in significant reduction in monocyte/macrophage cell num-
bers within PBMCs and elevated levels of IL-6/TNFα , in a dose-dependent manner, following ex vivo expo-
sure, with only SmCl3@SWCNT-mAb influencing PBMC cell viability. Monocyte/macrophage depletion was not 
observed in vivo after tail vein injection of 150 μ g of the conjugates per mouse. The lack of inducing immunologi-
cal responses after i.v. injection in mice is encouraging to warrant carrying out future pre-clinical tumor targeting 
and therapy studies using the radioactive (Sm-153)-filled and Cetuximab-functionalized SWCNTs (3).
Methods
SWCNT conjugates. As-received Elicarb® SWCNTs (Thomas Swan & Co. Ltd.) were steam- (4 h, 900 °C) 
and HCl-treated to remove carbonaceous impurities57, graphitic particles and metal particles (catalyst). The steam 
treatment also shortens the length of the SWCNTs, leading to a sample with a median length of 420 nm58. Short 
SWCNTs are of interest when developing delivery vehicles since they present an enhanced biocompatibility. Next, 
the short and purified SWCNTs were filled with anhydrous SmCl3 by molten phase capillary wetting following 
a previously reported protocol29. Empty amino-functionalized SWCNTs [SWCNT-NH2 (1)], samarium chlo-
ride-filled amino-functionalized SWCNTs [SmCl3@SWCNT-NH2 (2)], and filled SWCNTs functionalized with 
the targeting antibody Cetuximab [SmCl3@SWCNT-mAb (3)] were prepared according to reported procedures 
and thoroughly characterized29, as described in Supplementary Information. SmCl3@SWCNT-mAb conjugate 
corresponds to samarium chloride filled single-walled nanotubes with sealed ends that have been functionalized 
with amino groups first, and subsequently with the monoclonal antibody Cetuximab.
Homogenous stock suspensions of the three types of nanotubes at 1 mg/ml were prepared from the solid 
material by addition of sterile water. The suspensions were diluted to the desired concentrations for the cellular 
experiments using the appropriate cell culture media (see below).
Figure 8. Percentage of monocyte/macrophage population within PBMCs after tail vein injection of the 
conjugates in mice. C57Bl6 mice were injected via the tail vein with 150 μ l of one of the conjugates (1 mg/ml),  
PBS (negative control), LPS (3 mg/kg) (positive control). Whole blood was collected at 1, 7 and 13 days 
post-injection and cells were stained for CD3e (LT), CD45R/B220 (LB) or CD11b (monocytes/macrophages) 
expression. Percentage of CD11b+ cells (monocytes/macrophages) in PBMCs was calculated. Values are 
expressed as mean ± SD (n = 4). **p < 0.01 with respect to the other samples.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:42605 | DOI: 10.1038/srep42605
Cell culture. RAW 264.7 macrophages. RAW 264.7 murine macrophage cell line was obtained from 
American Type Culture Collection (ATCC). Cells were cultured in RPMI 1640 supplemented with 10% heat inac-
tivated Fetal Bovine Serum (FBS), 100 U/ml gentamycin, β -mercaptoethanol (50 μ M) and HEPES (20 mM) under 
controlled atmosphere (37 °C, 5% CO2). When confluency reached 70–80%, RAW 264.7 cells were detached with 
SE buffer (PBS containing 2 mM EDTA and 2% FBS), reseeded onto 96 well plates at a density of 105 cells/well and 
allowed to adhere overnight (37 °C, 5% CO2) prior to SWCNT addition.
Human PBMCs. As previously described59, leukocyte-rich buffy coats from healthy adult donors were obtained 
from the French Blood Bank (Etablissement Français du Sang, Strasbourg, France) and PBMCs were collected by 
Ficoll-Histopaque (Sigma-Aldrich 10771) density gradient centrifugation. The experiments were performed on 
cells from at least 3 different donors. Directly after isolation, PBMCs were incubated for 6 h (37 °C, 5% CO2) in 96 
well plates (106 cells/well) in complete RPMI 1640 medium (i.e. containing 10% heat inactivated FBS, 10 mg/ml 
gentamycin, and 10 mM HEPES; Lonza) prior to be exposed to the SWCNTs.
Viability and apoptosis in RAW 264.7 and PBMCs. Cytotoxicity of SWCNTs was evaluated by flow 
cytometry. For this purpose, RAW 264.7 cells and PBMCs were treated with 1, 10, 25, 50 and 100 μ g/ml of 
SWCNT-NH2 (1), SmCl3@SWCNT-NH2 (2) or SmCl3@SWCNT-Ab (3). DMSO (20%) was used as death positive 
control and lipopolysaccharide (LPS, 1 mg/ml) in combination with interferon-γ (IFN-γ , 1 ng/ml) as a positive 
control for cytokine production. After 24 h incubation, supernatants were collected for cytokine determination 
and cells were harvested with SE buffer and stained with both APC-Annexin V (AnnV; BD Pharmingen 550475) 
and propidium iodide (PI, 0.2 μ g/ml; Sigma-Aldrich) in a calcium containing buffer for 30 min in darkness.
In addition, in the case of PBMCs, different subpopulations were differentiated by means of cell surface mark-
ers (clusters of differentiation [CD]). Mouse anti-human PE-CD3 (BD 555340), FITC-CD19 (BD 555412) and 
PerCP-Cy5.5-CD14 (BD 555787) from BD Biosciences (Mountain View, CA, USA) were employed to detect and 
gate T lymphocytes, B lymphocytes and monocytes/macrophages, respectively.
Early apoptosis is shown by AnnV positive staining; double AnnV and PI stained cells are considered necrotic 
or late apoptotic, while the absence of staining shows viable cells. The percentage of live (AnnV− /PI− ), early 
apoptotic (AnnV+ /PI− ) and late apoptotic/necrotic (AnnV+ /PI+ and AnnV− /PI+ ) cells was determined by 
acquiring at least 50,000 events using a Gallios flow cytometer (Beckman Coulter, Villepinte-France) and analyz-
ing the data with Flowing Software 2.5.1.
Cell activation experiments in RAW 264.7 cells. Flow cytometry was employed to analyze cellu-
lar activation through CD86 expression evaluation in RAW 264.7 macrophages. Briefly, cells were incubated 
with 1, 10, 25, 50 and 100 μ g/ml of SWCNT-NH2 (1), SmCl3@SWCNT-NH2 (2) or SmCl3@SWCNT-mAb (3). 
Twenty-four hours later macrophages were detached with SE buffer, washed and stained for 30 minutes with 
PE-Rat Anti-Mouse CD86 fluorescent antibody (Clone GL1, BD Pharmingen 553692) and subjected to flow 
cytometry analysis. LPS (1 mg/ml) combined with IFN-γ (1 ng/ml) was used as positive control. Percentage 
of CD86+ cells was determined by acquiring at least 25,000 events using a Gallios flow cytometer (Beckman 
Coulter, Villepinte-France) and analyzing the data with Flowing Software 2.5.1.
Animals. All experimental methods on animal were approved by the UK Home office (PPL 70/7493) and 
were carried out in accordance with the UKCCCR Guidelines. Twenty female C57Bl/6 mice aged 5–6 weeks 
(Charles River Laboratories, UK) were caged in groups of four with free access to food and water. A tempera-
ture of 19– 22 °C was maintained, with a relative humidity of 45– 65%, and a 12 h light/dark cycle. Four mice per 
group and time point were anaesthetized by isoflurane inhalation and intravenously (i.v.) injected with 150 μ g 
of SWCNT-NH2 (1), SmCl3@SWCNT-NH2 (2) or SmCl3@SWCNT-mAb (3) in 150 μ l of PBS via a single tail 
vein injection. We used only PBS in the negative control group. An intraperitoneal injection of LPS (3 mg/kg) 
was administered to the positive control group. Thirteen days post-injection the animals were sacrificed by an 
intraperitoneal lethal dose of pentobarbital. The weight of the animals was monitored throughout the entire 
experiment.
Murine immune cells subpopulation analysis. Samples of 150 μ l of blood were collected from the tail 
vein of the animals at specific time points post-injection (1, 7 and 13 days) and PBMCs were isolated to analyze 
the immunological impact on them. Briefly, heparinized blood was centrifuged at 1000 × g for 10 min. Serum 
was separated and kept at − 20 °C for further cytokine analyses. Remaining sample was washed with 1 ml PBS and 
centrifuged at 1500 rpm. Supernatant was then discarded and cells were treated for 30 min in darkness with PE 
Hamster Anti-Mouse CD3e (BD 553063), FITC Rat Anti-Mouse CD45R/B220 (553087) and PerCP-Cy5.5 Rat 
Anti-Mouse CD11b (BD 561114) in order to stain T lymphocytes, B lymphocytes and monocytes/macrophages, 
respectively. Afterwards, samples were centrifuged, supernatant discarded and cells treated with ammonium 
chloride potassium buffer (ACK) to eliminate red blood cells. After a final centrifugation, supernatant was again 
discarded and cells were resuspended in PBS before being subjected to flow cytometry analysis. The percentage of 
cells in each subpopulation was determined by acquiring at least 5,000 events using a FACSCalibur flow cytome-
ter (BD, Franklin Lakes, NJ) and analyzing the data with Flowing Software 2.5.1.
Cytokine determination. RAW 264.7 macrophages and in vivo samples. Secretion of IL-6 and TNFα by 
RAW 264.7 macrophages or by in vivo treated mice was assayed using a double-sandwich ELISA. Polyvinyl microtiter 
plates were coated with 50 μ l/well of Specific Purified Rat Anti-Mouse IL-6 (BD Pharmingen 554400) or Specific 
Purified Rat Anti-Mouse TNFα (BD Pharmingen 557516) diluted in 0.05 M carbonate pH 9.6 buffer and 
incubated overnight at 4 °C. After washings with PBS containing 0.05% Tween (PBS-T), a saturation step was 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7:42605 | DOI: 10.1038/srep42605
performed by adding 100 μ l/well of PBS containing 10% FBS for 1 h at 37 °C. Plates were then washed with PBS-T 
and 50 μ l of culture supernatants (or serum in the case of mice samples) were added for 2 h at 37 °C. Plates were 
then washed with PBS-T and 50 μ l/well of secondary Biotin Rat Anti-Mouse IL-6 (BD Pharmingen 554402) or 
secondary Biotin Rat Anti-Mouse TNFα (BD Pharmingen 557432) were added and incubated for 1 h at room 
temperature. Then, plates were washed with PBS-T, and 50 μ l/well of streptavidin conjugated to horseradish per-
oxidase (diluted 1/500) were added. The plates were incubated for 30 min at room temperature, and then washed 
extensively with PBS-T and distilled H2O. The enzymatic reaction, revealing the presence of cytokines in the 
tested supernatants, was visualized by adding 3,3′ ,5,5′ -tetramethylbenzidine in the presence of H2O2. The result-
ing absorbance was measured at 450 nm after the reaction was stopped with 1 N HCl. Recombinant mouse IL-6 
(BD Pharmingen 554582) or recombinant mouse TNFα (BD Pharmingen 554589) were used as standards.
Human PBMCs. Secretion of IL-6 and TNFα by PBMCs was assayed using a double-sandwich ELISA following 
the manufacturer’s instructions in BD OptEIA™ Human IL-6 ELISA Set 555220 and BD OptEIA™ Human TNF 
ELISA Set 555212, respectively.
Statistical analysis. Mean values and standard deviation (S.D.) are plotted in each graph. Statistical analysis 
was performed with SPSS 19.0 (SPSS® , Chicago, IL, USA). Normal distribution of samples was assessed by the 
Shapiro–Wilk test, and homogeneity of variance by the Levene test. The data from the different SWCNT con-
jugates were compared with ANOVA followed by Bonferroni’s post-test. Statistically significant differences are 
considered at p < 0.05.
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